DJIA 15,955.96 295.78 1.89%
NASDAQ 4,335.73 68.89 1.61%
S&P 500 1,862.02 32.94 1.80%
market minute promo


106.84 0.14 (0.13%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BAYRY $106.84 0.13%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $105.94
Previous Close $106.70
Daily Range $105.45 - $106.92
52-Week Range $104.55 - $156.77
Market Cap $88.3B
P/E Ratio 592.78
Dividend (Yield) $0.00 (1.7%)
Volume 72,358
Average Daily Volume 119,799
Current FY EPS $7.79





Bayer AG (ADR) (BAYRY) Description

The Company offers products, including ethical pharmaceuticals and other health care products, agricultural products and polymers. Website:

News & Commentary

Eylea's Slowing Sales Growth Sends Regeneron Pharmaceutical Inc.'s Shares Lower

Sales and profits of Regeneron's best-selling drug come up a bit short of expectations.

Will 2016 Be Organovo Holdings, Inc.'s Best Year Yet?

3 reasons this 3D bioprinting company might be in for a Happy New Year.

Why Regeneron Pharmaceuticals Shares Jumped 32% in 2015

Shares catapulted higher last year because of increasing sales of its vision-restoring drug Eylea and a recent FDA approval.

The DuPont-Dow Chemical Merger: A Lot of Hype or a Long-Term Opportunity?

The two companies plan to merge and then split into three separate entities. Is there any way to tell how this will shake out?

These Approved and Developing Drugs Had a Major Impact on Patient Survival in 2015

Four drugs made a huge impact on patient survival in 2015 according to clinical trials, and one of them can be bought over the counter.

The 3 Most Important Drugs in Isis Pharmaceuticals' Pipeline

Isis Pharmaceuticals has a whopping 30 drugs currently in clinical trials, but how these three fare will be key to its future.

Why Cempra Inc is Up Big Today

An updated investor presentation appears to have bulls excited, and shares are soaring today as a result.

Is Cempra's 33% Drop Warranted?

Cempra's stock sells off hard on good news. Is the stock now a bargain?

Regeneron's Knock-out Quarter Could Be Just The Beginning

Regeneron's sales and income are soaring and new drug launches could lead to even better results in the future.

The Totally Benign Reason Monsanto Wants to Acquire Syngenta

While there's much talk about further controlling the food supply and being a greedy corporation, few are considering the potential environmental benefits behind Monsanto's bid for Syngenta.

See More BAYRY News...

BAYRY's Top Competitors

BAYRY $106.84 (0.13%)
Current stock: BAYRY
JNJ $101.80 (0.10%)
Current stock: JNJ
NVS $72.71 (0.70%)
Current stock: NVS
RHHBY $31.29 (0.47%)
Current stock: RHHBY